UY30281A1 - Compuestos heterociclicos del tipo piridinas y piridazinas sustituidas, particularmente 4-(4-clorofenilamino)-7-(2-metilaminocarbonil-4-piridilmetoxi)furo-(2,3-d)piridazina, sales, polimorfos, solvatos o hidratos, composiciones y aplicaciones - Google Patents

Compuestos heterociclicos del tipo piridinas y piridazinas sustituidas, particularmente 4-(4-clorofenilamino)-7-(2-metilaminocarbonil-4-piridilmetoxi)furo-(2,3-d)piridazina, sales, polimorfos, solvatos o hidratos, composiciones y aplicaciones

Info

Publication number
UY30281A1
UY30281A1 UY30281A UY30281A UY30281A1 UY 30281 A1 UY30281 A1 UY 30281A1 UY 30281 A UY30281 A UY 30281A UY 30281 A UY30281 A UY 30281A UY 30281 A1 UY30281 A1 UY 30281A1
Authority
UY
Uruguay
Prior art keywords
pyridazines
piridylmetoxy
piridazoros
piridines
chlorophenylamine
Prior art date
Application number
UY30281A
Other languages
English (en)
Inventor
Dr Olaf Christensen
Dr Reiner Frey
Dr Bernd Riedl
Dr Martina Klein
Dr Peter Sandner
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of UY30281A1 publication Critical patent/UY30281A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invencion se refiere a composiciones farmacéuticas y combinaciones para tratar, prevenir o atender la hipertension pulmonar que comprenden productos farmacéuticos heterocíclicos de moléculas pequenas y, más en particular, piridinas y piridazinas sustituidas combinadas opcionalmente con al menos un agente terapéutico adicional.
UY30281A 2006-04-15 2007-04-12 Compuestos heterociclicos del tipo piridinas y piridazinas sustituidas, particularmente 4-(4-clorofenilamino)-7-(2-metilaminocarbonil-4-piridilmetoxi)furo-(2,3-d)piridazina, sales, polimorfos, solvatos o hidratos, composiciones y aplicaciones UY30281A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06007929 2006-04-15

Publications (1)

Publication Number Publication Date
UY30281A1 true UY30281A1 (es) 2007-11-30

Family

ID=38190754

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30281A UY30281A1 (es) 2006-04-15 2007-04-12 Compuestos heterociclicos del tipo piridinas y piridazinas sustituidas, particularmente 4-(4-clorofenilamino)-7-(2-metilaminocarbonil-4-piridilmetoxi)furo-(2,3-d)piridazina, sales, polimorfos, solvatos o hidratos, composiciones y aplicaciones

Country Status (10)

Country Link
US (1) US8304406B2 (es)
EP (1) EP2010173A1 (es)
JP (1) JP2009533479A (es)
AR (1) AR060431A1 (es)
CA (1) CA2648957A1 (es)
DO (1) DOP2007000073A (es)
PE (1) PE20080534A1 (es)
TW (1) TW200808317A (es)
UY (1) UY30281A1 (es)
WO (1) WO2007118602A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201502763VA (en) 2012-11-08 2015-05-28 Pfizer Heteroaromatic compounds and their use as dopamine d1 ligands
WO2015089105A1 (en) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
CN105294686B (zh) * 2015-11-30 2017-03-22 郑州大明药物科技有限公司 一种利奥西呱的制备方法
WO2018080216A1 (en) * 2016-10-28 2018-05-03 Daewoong Pharmaceutical Co., Ltd. Phenyl phthalazine derivative, method for the preparation thereof, and pharmaceutical composition comprising the same
CN107129502B (zh) * 2017-04-13 2022-08-05 泰州亿腾景昂药业股份有限公司 EOC315 Mod.I晶型化合物及其制备方法
CN109232546B (zh) * 2018-09-25 2020-09-04 中国人民解放军总医院 一种嘧啶磺酰胺类衍生物的医药用途
EP4087561A4 (en) * 2020-01-07 2024-02-14 Shanghai Huayu Biotechnology Co., Ltd. COMBINATION CANCER THERAPY WITH CHK INHIBITOR
US20240294537A1 (en) 2021-07-07 2024-09-05 Teva Pharmaceuticals International Gmbh SOLID STATE FORMS OF 4-[[4-(4-CHLOROANILINO)FURO[2,3-d]PYRIDAZIN-7-yl]OXYMETHYL]-N-METHYLPYRIDINE-2-CARBOXAMIDE AND SALT THEREOF

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1107964B8 (en) * 1998-08-11 2010-04-07 Novartis AG Isoquinoline derivatives with angiogenesis inhibiting activity
CO5200835A1 (es) * 1999-09-28 2002-09-27 Bayer Corp Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis
WO2002055099A2 (en) * 2000-12-01 2002-07-18 Xoma Technology Ltd Modulation of pericyte proliferation using bpi protein products or bpi inhibitors
US20050019424A1 (en) * 2001-12-21 2005-01-27 Adams Paul E. Anti-angiogenesis combination therapies comprising pyridazine or pyridine derivatives
DE10310908A1 (de) 2003-03-13 2004-09-23 Bayer Healthcare Ag Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von pulmonaler Hypertonie
EP1740203A4 (en) * 2004-03-31 2008-02-13 Eyegene Inc POLYPEPTIDE INDUCING THE ANGIOPOIETINE SECRETION
CN101031293A (zh) * 2004-05-06 2007-09-05 普莱希科公司 Pde4b抑制剂及其应用
EP1746099A1 (en) 2004-12-23 2007-01-24 DeveloGen Aktiengesellschaft Mnk1 or Mnk2 inhibitors
JP5155171B2 (ja) 2005-10-06 2013-02-27 アストラゼネカ・アクチエボラーグ 新規化合物

Also Published As

Publication number Publication date
US8304406B2 (en) 2012-11-06
AR060431A1 (es) 2008-06-18
WO2007118602A1 (en) 2007-10-25
JP2009533479A (ja) 2009-09-17
CA2648957A1 (en) 2007-10-25
DOP2007000073A (es) 2007-11-15
PE20080534A1 (es) 2008-07-13
TW200808317A (en) 2008-02-16
EP2010173A1 (en) 2009-01-07
US20100113452A1 (en) 2010-05-06

Similar Documents

Publication Publication Date Title
UY30281A1 (es) Compuestos heterociclicos del tipo piridinas y piridazinas sustituidas, particularmente 4-(4-clorofenilamino)-7-(2-metilaminocarbonil-4-piridilmetoxi)furo-(2,3-d)piridazina, sales, polimorfos, solvatos o hidratos, composiciones y aplicaciones
HN2005000255A (es) Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
CY1119669T1 (el) Παραγωγα 1-φαινυλ-2-πυριδινυλ-αλκυλ-αλκοολων ως αναστολεις φωσφοδιεστερασης
CO6480932A2 (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida.
UY30314A1 (es) Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmacéuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion
GT200900027A (es) Compuestos organicos
AR078846A1 (es) Composicion para el tratamiento de la enfermedad de alzheimer
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
CR9953A (es) Diarilurea para el tratamiento de hipertension pulmonar
CR9602A (es) Nuevos derivados de 2,4-dianilinpirimidinas, su preparacion, como medicamentos, composiciones farmaceuticas y particularmente como inhibidores de ikk
UY28958A1 (es) Nuevos derivados de piridazin-3(2h)-ona
DOP2010000134A (es) Algunos derivados de 2-pirazinona como inhibidores de elastasa de los neutrofilos
BRPI0709266B8 (pt) 5-(hidroximetileno e aminometileno) pirimidinas substituídas e composição farmacêutica que as compreende
UY31631A1 (es) Nuevos derivados de 7-fenil-7h-pirrolo-[2,3d]-pirimidin-2-il-amino, sales de los mismos, procesos para su preparacion, composiciones farmacéuticas que los comprenden y aplicaciones
WO2007064931A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
UY31027A1 (es) Derivados de tetrahidroindol y tetrahidroindazol
ECSP088852A (es) Azolopirimidinas como inhibidores de la actividad canabinoidea 1
UY29902A1 (es) Diarilureas para el tratamiento de la hipertensión pulmonar
DOP2009000165A (es) Derivados de oxindol sustituido, medicamentos que los comprenden y uso de los mismos
CU20100111A7 (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso para el tratamiento y prevención de enfermedades pulmonares y cardiovasculares
BRPI0816798A2 (pt) composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
CL2008000596A1 (es) Forma de dosificacion que comprende 1-(6-[(3-ciclobutil-2,3,4,5-tetrahidro-1h-3-benzazepin-7-il)oxi]-3-piridinil)-2-pirrolidinona, un estabilizador, un excipiente; procedimiento de preparacion; y su uso para tratar enfermedades neurologicas.
BR112015023878A2 (pt) composto, composição farmacêutica, e, uso de um composto
UY30029A1 (es) Derivados de piperidina, sus sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolos y aplicaciones
MX2019012375A (es) Formulaciones del inhibidor del antigeno-1 asociado a la funcion de linfocitos (lfa-1).

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170606